Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis

Human Reproduction Update

Volumn 12, Issue 6, 2006, Pages 651-671

  Kolibianakis, E M ^a   Collins, J ^b   Tarlatzis, B C ^a   Devroey, P ^c   Diedrich, K ^d   Griesinger, G ^d  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b MCMASTER UNIVERSITY   (Canada)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

GnRH agonist; GnRH antagonist; Live birth; Ovarian stimulation

Indexed keywords

BUSERELIN; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; ESTRADIOL VALERATE; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; NAFARELIN ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; TRIPTORELIN; UROFOLLITROPIN;

BIRTH; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG USE; EXPERIMENTAL DESIGN; FERTILIZATION IN VITRO; HORMONE INHIBITION; HUMAN; HYPOPHYSIS; INFORMATION RETRIEVAL; MEDICAL LITERATURE; META ANALYSIS; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PEER REVIEW; PREGNANCY; PRIORITY JOURNAL; PROBABILITY; PUBLISHING; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

FEMALE; FERTILITY AGENTS; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; LIVE BIRTH; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; PROBABILITY;

EID: 33750210002     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dml038     Document Type: Review

References (46)

1. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E and Bahceci M (2001) Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: Results of a prospective randomized trial. Hum Reprod 16,868-870.
2. Al-Inany H and Aboulghar M (2002) GnRH antagonist in assisted reproduction: A Cochrane review. Hum Reprod 17,874-885.
3. Albano C, Felberbaum RE, Smitz J, Riethmuller-Winzen H, Engel J, Diedrich K and Devroey P (2000) Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 15,526-531.
4. Arce JC, Nyboe Andersen A and Collins J (2005) Resolving methodological and clinical issues in the design of efficacy trials in assisted reproductive technologies: A mini-review. Hum Reprod 20,1757-1771.
5. Badrawi A, Al-Inany H, Hussein M, Zaki S and Ramzy A (2005) Agonist vs. antagonist in ICSI cycles: A randomized trial and cost-effectiveness analysis. MEFS J 10,49-54.
6. Bahceci M, Ulug U, Ben-Shlomo I, Erden HF and Akman MA (2005) Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: A randomized, prospective, pilot study. J Reprod Med 50,84-90.
7. Barmat LI, Chantilis SJ, Hurst BS and Dickey RP (2005) A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization. Fertil Steril 83,321-330.
8. Borm G and Mannaerts B (2000) Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multi-centre trial. The European Orgalutran Study Group. Hum Reprod 15,1490-1498.
9. Check ML, Check JH, Choel JK, Davies E and Kiefer D (2004) Effect of antagonists vs agonists on in vitro fertilization outcome. Clin Exp Obstet Gynecol 31,257-259.
10. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC and Haines CJ (2005) GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: A randomized controlled trial. Hum Reprod 20,616-621. The Cochrane Collaboration (2000) Review manager (RevMan) [4.1]. The Cochrane Collaboration, Oxford.
11. Delvigne A and Rozenberg S (2001) Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 16,2491-2495.
12. Delvigne A and Rozenberg S (2002) Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update 8,559-577.
13. Deutsches IVF Register (2004) Annual report from the German IVF registry 2004. Available from http://www.deutsches-ivf-register.de
14. European and Middle East Orgalutran Study Group (2001) Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 16,644-651.
15. Fauser BC and Devroey P (2005) Why is the clinical acceptance of gonadotropin- releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 83,1607-1611.
16. Fauser BC, Devroey P and Macklon NS (2005) Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 365,1807-1816.
17. Fluker M, Grifo J, Leader A, Levy M, Meldrum D, Muasher SJ, Rinehart J, Rosenwaks Z, Scott RT Jr, Schoolcraft W et al. (2001) Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 75,38-45.
18. Franco JG Jr, Baruffi LRL, Petersen CG, Mauri CG, Felipe V and Contart P (2003) Comparison of ovarian stimulation with recombinant FSH after 2nd phase protocols with GnRH analogs (I-Estradiol + Ganirelix versus II-Nafarelin). J Brasileiro Reprod Assist 7,27-33.
19. Germond M, Urner F, Chanson A, Primi MP, Wirthner D and Senn A (2004) What is the most relevant standard of success in assisted reproduction? The cumulated singleton/twin delivery rates per oocyte pick-up: The CUSIDERA and CUTWIDERA. Hum Reprod 19,2442-2444.
20. Griesinger G, Dafopoulos K, Schultze-Mosgau A, Felberbaum R and Diedrich K (2004) What is the most relevant standard of success in assisted reproduction? Is BESST (birth emphasizing a successful singleton at term) truly the best? Hum Reprod 19,1239-1241.
21. Griesinger G, Felberbaum R and Diedrich K (2005) GnRH antagonists in ovarian stimulation: A treatment regimen of clinicians' second choice? Data from the German national IVF registry. Hum Reprod 20,2373-2375.
22. Griesinger G, Dawson A, Schultze-Mosgau A, Finas D, Diedrich K and Felberbaum R (2006) Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol. Fertil Steril 85, 791-793.
23. Heijnen EM, Macklon NS and Fauser BC (2004) What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: Consider the whole treatment. Hum Reprod 19,1936-1938.
24. Hohmann FP, Macklon NS and Fauser BC (2003) A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 88,166-173.
25. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH et al. (2004) Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: A prospective randomized study. Hum Reprod 19,1993-2000.
26. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B and Itskovitz-Eldor J (1999) High doses of gonadotrophinreleasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 14,2242-2244.
27. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2003) Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: Effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab 88,5632-5637.
28. Kolibianakis EM, Zikopoulos K, Smitz J, Camus M, Tournaye H, Van Steirteghem AC and Devroey P (2004) Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertil Steril 82,223-226.
29. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN and Yang YS (2005) Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril 83,1700-1707.
30. Loutradis D, Stefanidis K, Drakakis P, Milingos S, Antsaklis A and Michalas S (2004) A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol. Fertil Steril 82,1446-1448.
31. Malmusi S, La Marca A, Giulini S, Xella S, Tagliasacchi D, Marsella T and Volpe A (2005) Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation. Fertil Steril 84,402-406.
32. Marci R, Caserta D, Dolo V, Tatone C, Pavan A and Moscarini M (2005) GnRH antagonist in IVF poor-responder patients: Results of a randomized trial. Reprod Biomed Online 11,189-193.
33. Martínez F, Coroleu B, Marqués L, Parera N, Buxaderas R, Tur R and Barri PN (2003) Comparación del "Protocolo Corto" versus "Antagonistas" con o sin Citrato de Clomifeno para estimulación en FIV de pacientes con "baja respuesta". Rev Ibero Am Fertil 2025-2360.
34. Messinis IE, Loutradis D, Domali E, Kotsovassilis CP, Papastergiopoulou L, Kallitsaris A, Drakakis P, Dafopoulos K and Milingos S (2005) Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Hum Reprod 20,3192-3197.
35. Min JK, Breheny SA, MacLachlan V and Healy DL (2004) What is the most relevant standard of success in assisted reproduction? The singleton, term gestation, live birth rate per cycle initiated: The BESST endpoint for assisted reproduction. Hum Reprod 19,3-7.
36. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P and Frydman R (2000) Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 73,314-320.
37. Roulier R, Chabert-Orsini V, Sitri MC, Barry B and Terriou P (2003) Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment. Reprod Biomed Online 7,185-189.
38. Sauer MV, Thornton MH 2nd, Schoolcraft W and Frishman GN (2004) Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 9,487-493.
39. Schmidt DW, Bremner T, Orris JJ, Maier DB, Benadiva CA and Nulsen JC (2005) A randomized prospective study of microdose leuprolide versus ganirelix in in vitro fertilization cycles for poor responders. Fertil Steril 83,1568-1571.
40. Seelig AS, Al-Hasani S, Katalinic A, Schopper B, Sturm R, Diedrich K and Ludwig M (2002) Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril 77,472-475.
41. Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B et al. (2005) Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 20,3318-3327.
42. Tarlatzis B, Fauser BC, Kolibianakis EM, Diedrich K and Devroey P (2006) GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 12,333-340.
43. Tiitinen A, Hyden-Granskog C and Gissler M (2004) What is the most relevant standard of success in assisted reproduction?: The value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten. Hum Reprod 19,2439-2441.
44. Vlaisavljevic V, Reljic M, Lovrec VG and Kovacic B (2003) Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles - a prospective, randomized study. Reprod Biomed Online 7,301-308.
45. Xavier P, Gamboa C, Calejo L, Silva J, Stevenson D, Nunes A and Martinez-de-Oliveira J (2005) A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: Effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 120,185-189.
46. Zikopoulos K, Kolibianakis EM, Camus M, Tournaye H, Van den Abbeel E, Joris H, Van Steirteghem A and Devroey P (2004) Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertil Steril 81,473-475.